

ESPS Peer-review Report

Name of Journal: World Journal of Clinical Cases

ESPS Manuscript NO: 3460

Title: A long lasting response to second-line everolimus in kidney cancer

Reviewer code: 00736564

Science editor: Wang, Jin-Lei

Date sent for review: 2013-05-03 13:37

Date reviewed: 2013-05-04 22:09

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This is very interesting case showing promising PFS for some patients with RCC. However, authors should include much better and longer discussion which should be more informative and educational for the readers. They should point out what are their thoughts in the light of published literature why this treatment worked in this patient, what would be their recommendation for selection of the patients for clinical trial of everolimus in 2nd line therapy. It would be interesting if the authors could explain how it happened that patient who had close clinical and radiological follow up ended to have multiple metastasis with the biggest one having 10cm. Also there are some misspelling issues that should be sorted before publication of the article.

ESPS Peer-review Report

Name of Journal: World Journal of Clinical Cases

ESPS Manuscript NO: 3460

Title: A long lasting response to second-line everolimus in kidney cancer

Reviewer code: 00740391

Science editor: Wang, Jin-Lei

Date sent for review: 2013-05-03 13:37

Date reviewed: 2013-05-05 00:32

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

This represents a single case of extended response to everolimus. Further research is required in evaluating specific prognostic factors, which, may prolong progression free survival in select patients undergoing this treatment. Thank you for your contribution.

ESPS Peer-review Report

Name of Journal: World Journal of Clinical Cases

ESPS Manuscript NO: 3460

Title: A long lasting response to second-line everolimus in kidney cancer

Reviewer code: 00505635

Science editor: Wang, Jin-Lei

Date sent for review: 2013-05-03 13:37

Date reviewed: 2013-05-06 18:26

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

The use of new anti-angiogenetic agents have changed the current status of treating locally advanced and/or metastatic renal cell cancer. As the relevant experience is limited, the topic of this case report is interesting. In the Introduction the authors could stress the issue of renal cancer pathogenetics by including the following reference in the revised manuscript: Am J Nephrol. 2006;26(3):218-31